Danaher Corp.

DHR-N

NYSE:DHR

205.73
1.46 (0.70%)
The Danaher Corporation is an American company with its headquarters in Washington, D.C., United States. Its products are concentrated in the fields of design, manufacturing, and marketing of industrial and consumer products.
More at Wikipedia

Analysis and Opinions about DHR-N

Signal
Opinion
Expert
WATCH
WATCH
April 20, 2020
It is rather like a 3-M, a healthcare services like company, diagnostics, etc. He thinks it is a fabulous company. Maybe you want to hold this for a longer period of time. Margins may be peaking, however. In the US healthcare is tied to employment. The dividend is actually quite small. You want to focus on this in the post-COVID-19 environment.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
April 20, 2020
It is rather like a 3-M, a healthcare services like company, diagnostics, etc. He thinks it is a fabulous company. Maybe you want to hold this for a longer period of time. Margins may be peaking, however. In the US healthcare is tied to employment. The dividend is actually quite small. You want to focus on this in the post-COVID-19 environment.
PAST TOP PICK
PAST TOP PICK
February 7, 2020

(A Top Pick Jan 17/19, Up 54%) A life-sciences companies that also does consumables and mass spectrometers. They recently purchased the GE biopharma section. They have big margins coming into the company. Earnings were higher than their peer group. He has owned this since 2013 and he sees no reason to sell it. He wouldn't enter now with 30x earnings. It works as a core holding since life science has good growth potential.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
February 7, 2020

(A Top Pick Jan 17/19, Up 54%) A life-sciences companies that also does consumables and mass spectrometers. They recently purchased the GE biopharma section. They have big margins coming into the company. Earnings were higher than their peer group. He has owned this since 2013 and he sees no reason to sell it. He wouldn't enter now with 30x earnings. It works as a core holding since life science has good growth potential.

COMMENT
COMMENT
February 4, 2020
As a roll-up It was a roll-up, but not now. The new DHR is a producer of filtration systems and single-use consumables that help make biotech drugs. They have a leading market share, supplying most major biotechs around the world. He likes it. Little is built into the numbers now and investors are very conservative about forecasting the biotech drug market.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
February 4, 2020
As a roll-up It was a roll-up, but not now. The new DHR is a producer of filtration systems and single-use consumables that help make biotech drugs. They have a leading market share, supplying most major biotechs around the world. He likes it. Little is built into the numbers now and investors are very conservative about forecasting the biotech drug market.
SELL
SELL
January 13, 2020
They have been a successful franchise and acquisition story. His concern has always been valuation. This is a great company. It should be on your radar. It is too expensive so you should sell it.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 13, 2020
They have been a successful franchise and acquisition story. His concern has always been valuation. This is a great company. It should be on your radar. It is too expensive so you should sell it.
PAST TOP PICK
PAST TOP PICK
January 13, 2020
(A Top Pick Oct 28/19, Up 17%) It's up 52% in the past year, but $10,000 returned over 30 years is now $2.3 million!
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 13, 2020
(A Top Pick Oct 28/19, Up 17%) It's up 52% in the past year, but $10,000 returned over 30 years is now $2.3 million!
TOP PICK
TOP PICK
October 28, 2019
A private equity company and a smart acquisitor. They bought GE's biopharma division which added debt to their books, but DHR has done buys like this before, knowing how to pay down debt yet be accretive to earnings. They have spun-off their dental division The dividend has grown 28% annually, though it is small now. Great for the long term. (Analysts’ price target is $152.14)
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
October 28, 2019
A private equity company and a smart acquisitor. They bought GE's biopharma division which added debt to their books, but DHR has done buys like this before, knowing how to pay down debt yet be accretive to earnings. They have spun-off their dental division The dividend has grown 28% annually, though it is small now. Great for the long term. (Analysts’ price target is $152.14)
BUY
BUY
March 21, 2019
They just bought GE Pharma for $20 billion that supposedly is going to be an earnings accretive acquisition. The stock went up in price $6 the day it was announced. The market basically saying "you did good". Now they sit back and pay down the debt in 5 years. There is going to be a bump in earnings. Still buying but it is getting toppish.
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
March 21, 2019
They just bought GE Pharma for $20 billion that supposedly is going to be an earnings accretive acquisition. The stock went up in price $6 the day it was announced. The market basically saying "you did good". Now they sit back and pay down the debt in 5 years. There is going to be a bump in earnings. Still buying but it is getting toppish.
TOP PICK
TOP PICK
January 17, 2019
Life sciences, diagnostics, and consumables for research, with huge demographic potential. Multinational. Looking at 10-15% dividend growth. Has owned it for the better part of a decade and it's never upset him. Yield is 0.6% (Analysts’ price target is $112.53)
Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 17, 2019
Life sciences, diagnostics, and consumables for research, with huge demographic potential. Multinational. Looking at 10-15% dividend growth. Has owned it for the better part of a decade and it's never upset him. Yield is 0.6% (Analysts’ price target is $112.53)
BUY
BUY
August 7, 2018

Danaher is like owning private equity. Serial acquisitors of businesses to improve and generate free cash flow well above working capital. In all the right categories right now. About to spin-off dental business. Into life sciences, consumables, and wastewater management. Growing nicely around 15%. Dividend growing 14% year over year, has grown 420% over last 15 years.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
August 7, 2018

Danaher is like owning private equity. Serial acquisitors of businesses to improve and generate free cash flow well above working capital. In all the right categories right now. About to spin-off dental business. Into life sciences, consumables, and wastewater management. Growing nicely around 15%. Dividend growing 14% year over year, has grown 420% over last 15 years.

PAST TOP PICK
PAST TOP PICK
January 29, 2018

(A Top Pick March 13/17. Up 19.26%) Along with all the life sciences companies, it’s been on a tear. This is because margins are growing. A lot of these are overseas. He likes this because they are in 4 major businesses, dental, water, environmental and all of the usable things for testing that are in laboratories. Still a Hold.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 29, 2018

(A Top Pick March 13/17. Up 19.26%) Along with all the life sciences companies, it’s been on a tear. This is because margins are growing. A lot of these are overseas. He likes this because they are in 4 major businesses, dental, water, environmental and all of the usable things for testing that are in laboratories. Still a Hold.

PAST TOP PICK
PAST TOP PICK
January 11, 2018

(A Top Pick March 13/17. Up 13%.) This is in 5 businesses, life sciences, diagnostics, water quality, product idea and dental. These are all industries that have burgeoning growth going forward. Danaher makes acquisitions of companies in those industries, and then turns them around. The dividend has been growing at roughly a 12%-15% clip, so a 13% return on the stock price is no surprise.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
January 11, 2018

(A Top Pick March 13/17. Up 13%.) This is in 5 businesses, life sciences, diagnostics, water quality, product idea and dental. These are all industries that have burgeoning growth going forward. Danaher makes acquisitions of companies in those industries, and then turns them around. The dividend has been growing at roughly a 12%-15% clip, so a 13% return on the stock price is no surprise.

TOP PICK
TOP PICK
March 13, 2017

This is in 4 basic businesses, which are all trends moving forward. They got rid of their industrial business about a year ago with a spinoff, and what is left is what he wants to own. Life sciences, diagnostics, dental and environment. Instead of owning oil and gas stocks, his resource of choice is water. This company does wastewater management. Long-term returns have been almost double what the S&P 500 has been over the last 5, 10, 20 years. These guys are like private equities. They come in and buy a company, but unlike the 3 Gs of the world, where they rip everything apart, they work with the owners and build the businesses as turnarounds. This is where the value added comes from. Dividend growth, free cash flow growth and revenue growth. In 3 of the 4 businesses, the margins are mid-teens and with the water business, it is up in the 20s, creating huge returns on capital. Yield of 0.6%. (Analysts’ price target is $89.82.)

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
March 13, 2017

This is in 4 basic businesses, which are all trends moving forward. They got rid of their industrial business about a year ago with a spinoff, and what is left is what he wants to own. Life sciences, diagnostics, dental and environment. Instead of owning oil and gas stocks, his resource of choice is water. This company does wastewater management. Long-term returns have been almost double what the S&P 500 has been over the last 5, 10, 20 years. These guys are like private equities. They come in and buy a company, but unlike the 3 Gs of the world, where they rip everything apart, they work with the owners and build the businesses as turnarounds. This is where the value added comes from. Dividend growth, free cash flow growth and revenue growth. In 3 of the 4 businesses, the margins are mid-teens and with the water business, it is up in the 20s, creating huge returns on capital. Yield of 0.6%. (Analysts’ price target is $89.82.)

BUY
BUY
July 6, 2016

(Market Call Minute.) Well-run company.

Show full opinionHide full opinion

(Market Call Minute.) Well-run company.

PAST TOP PICK
PAST TOP PICK
March 31, 2015

(A Top Pick July 15/14. Up 8.95%.) A multi-industrial with exposure to medical devices and your typical businesses as well. In this market, this is one of the better industrials to own, because it doesn’t have exposure to oil and gas. The new CEO has done a great job of navigating shareholders expectations. Feels they have a significant amount of CapX to do a deal. It is an M&A story, and people are waiting for the M&A to happen.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
March 31, 2015

(A Top Pick July 15/14. Up 8.95%.) A multi-industrial with exposure to medical devices and your typical businesses as well. In this market, this is one of the better industrials to own, because it doesn’t have exposure to oil and gas. The new CEO has done a great job of navigating shareholders expectations. Feels they have a significant amount of CapX to do a deal. It is an M&A story, and people are waiting for the M&A to happen.

PAST TOP PICK
PAST TOP PICK
December 15, 2014

(Top Pick Jul 15/14, Up 6.72%) Thinks they will migrate away from the industrial side and toward the medical/dental side. This is an M&A and rollup story. The stock looks cheaper now. The cash balance suggests they will do more M&A. Thinks there is still more upside.

Show full opinionHide full opinion
Danaher Corp. (DHR-N)
December 15, 2014

(Top Pick Jul 15/14, Up 6.72%) Thinks they will migrate away from the industrial side and toward the medical/dental side. This is an M&A and rollup story. The stock looks cheaper now. The cash balance suggests they will do more M&A. Thinks there is still more upside.

Showing 1 to 15 of 19 entries

Danaher Corp.(DHR-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Danaher Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Danaher Corp.(DHR-N) Frequently Asked Questions

What is Danaher Corp. stock symbol?

Danaher Corp. is a American stock, trading under the symbol DHR-N on the New York Stock Exchange (DHR). It is usually referred to as NYSE:DHR or DHR-N

Is Danaher Corp. a buy or a sell?

In the last year, 3 stock analysts published opinions about DHR-N. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is WATCH. Read the latest stock experts' ratings for Danaher Corp..

Is Danaher Corp. a good investment or a top pick?

Danaher Corp. was recommended as a Top Pick by Darren Sissons on 2020-04-20. Read the latest stock experts ratings for Danaher Corp..

Why is Danaher Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Danaher Corp. worth watching?

3 stock analysts on Stockchase covered Danaher Corp. In the last year. It is a trending stock that is worth watching.

What is Danaher Corp. stock price?

On 2020-08-14, Danaher Corp. (DHR-N) stock closed at a price of $205.73.